Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Canadian Institutes of Health Research (CIHR) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Preliminary studies suggest that COVID-19 causes long-term lung damage, even in young, otherwise healthy people who did not need to go to hospital or the ICU.
We seek to know how common long-term lung damage after COVID-19 is, who is most affected by it and what the effects of this damage are on other important aspects of people's lives. We plan to study a large sample of people with a history of COVID-19 infection from across Canada-some who needed hospitalization but most who did not. Through online questionnaires, we will determine their respiratory symptoms, quality of life and medical history. Then we will invite them to one of our thirteen Canadian testing centres to have special, thorough breathing tests.
We hypothesize that COVID-19 leaves a significant proportion of people with measurable respiratory impairment.
The information we learn about the effect of COVID-19 on the lungs will help patients and health care providers manage it better. It will also reveal how different COVID-19 variants affect the lungs. We will use this new knowledge to write a formal guide on what respiratory monitoring and testing should be done after COVID-19 infection. This will ensure that people affected by COVID-19 get the care they need to maintain their lung health.
We will prospectively recruit a representative, random sample of adult (age ≥ 18), community-dwelling patients, who have had a positive PCR test for COVID-19 infection and symptomatic infection five to 12 months previously.
This cross-sectional, observational study will have two phases:
Screening:
Screening for eligibility
Observation Period:
The study of COVID-19 infection and its long-term effects is constantly evolving. Over the course of this research study, new knowledge may become available that may lead to changes in the study's outcome measures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To determine the prevalence of respiratory post-acute sequelae of SARS-CoV-2 (PASC) and PASC | At five-12 months post positive PCR test for SARS-CoV-2 infection |
| Measure | Description | Time Frame |
|---|---|---|
| To determine risk factors for respiratory PASC | At five-12 months post positive PCR test for SARS-CoV-2 infection | |
| To determine the spectrum of severity of respiratory PASC | At five-12 months post positive PCR test for SARS-CoV-2 infection |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Not able to communicate with our research personnel (themselves or through a translator)
Not provided
Not provided
Not provided
Community sample
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrea Gershon, MD, MSc | Sunnybrook Health Sciences Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Paul's Hospital | Vancouver | British Columbia | Canada | |||
| Queen Elizabeth II Health Sciences Centre |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| To determine objective physiologic characteristics of respiratory PASC | At five-12 months post positive PCR test for SARS-CoV-2 infection |
| Halifax |
| Nova Scotia |
| Canada |
| St. Joseph's Healthcare Hamilton | Hamilton | Ontario | Canada |
| Kingston Health Sciences Centre | Kingston | Ontario | Canada |
| The Ottawa Hospital | Ottawa | Ontario | Canada |
| Sunnybrook Health Sciences Centre | Toronto | Ontario | M4N 3M5 | Canada |
| St. Michael's Hospital | Toronto | Ontario | Canada |
| Institut Universitaire de Cardiologie et de Pneumologie de Québec | Québec | Canada |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |